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Thesis A bstract

GLAST, GLT-1, EA ACl, and EAAT4 are high-affinity, sodium-dependent glutamate
transporters identified in the mammalian central nervous system (CNS). In this study, the
expression patterns of these transporter subtypes were characterized in two types of
primary cell cultures: cerebellar granule neurons (CGN) and mixed CGN/glial cultures.
Both culture types have been used extensively in studies o f glutamate-mediated
excitotoxicity. Cells were isolated from 7-day-old rat cerebella and grown for 10 days.
Obtaining > 90% pure CGN cultures was achieved by adding cytosine arabinoside to halt
the proliferation o f glial cells, whereas the mixed CGN/glial cell cultures were obtained
by permitting glial cell proliferation. Subtype-specific anti-peptide antibodies were used
to identify the glutamate transporters. Antibodies against neuronal cell markers (anti
neuronal nuclei (NeuN) and anti-neurofilament (NF)) and against an astrocyte marker
(anti-glial fibrillary acidic protein (GFAP)), were used to determine cell type specific
expression of the transporters. The results indicate that both CGN and mixed CGN/glial
cell cultures contain cells that are immunopositive for the glutamate transporters GLAST,
GLT-1, EA A C l, and EAAT4. While GLAST and GLT-1 are generally designated as
“glial glutamate transporters”, we report here that GLAST and GLT-1 immunostaining is
predominantly found on cells that are immunopositive for the neuronal cell markers, NF
and NeuN. The previously reported “neuronal glutamate transporter”, EA ACl, localizes
to NF and NeuN positive cells only in these culture systems. However, the previously
described “neuronal glutamate transporter”, EAAT4, localizes predominantly to GFAP
positive cells. These findings demonstrate that expression patterns in vitro do not
necessarily mimic previously reported in vivo glutamate transporter expression patterns.
Additionally, in the mixed CGN/glial cell cultures, we demonstrate that both GLAST and
EAAT4 appear to be expressed by a greater number of GFAP positive astrocytes than in
the CGN cultures. GLT-1 and EA ACl expression appears consistent between both
culture systems. These findings represent an important foundation for future studies
involving glutamate transporters, particularly as related to regulation of expression,
functional studies, developmental expression, and glutamate-mediated excitotoxicity.
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INTRODUCTION
L -G lutam ate

L-Glutamate (L-GLU) has attracted considerable attention in recent years because
o f its role as both the primary excitatory amino acid (EAA) neurotransmitter in the
mammalian central nervous system (CNS) and as a potent neurotoxin. Beginning with
the demonstration o f the convulsive properties o f L-GLU and the direct activation of
CNS neurons by this EAA, considerable effort has been directed toward establishing the
role o f L-GLU in fast excitatory neurotransmission (Curtis et al., 1959; Takahashi et al.,
1997; Bridges, 2001).

N um erous techniques including immunocytochemistry,

pharmacology, and electrophysiology collectively demonstrate that L-GLU exhibits the
classic characteristics o f a neurotransmitter. Thus, L-GLU is sequestered in synaptic
vesicles, released into the synaptic cleft in a C a ^ dependent manner, activates receptors
for signal propagation, and is rapidly transported into neurons and neighboring glial cells
for the purposes o f signal termination and transmitter recycling (Kanai et al., 1994a). In
addition to its role in standard fast synaptic communication, L-glutamate-mediated
neurotransmission plays a role in higher order signal processing (e.g., learning, memory,
developmental plasticity), as well as in neuropathology (e.g., Alzheimer’s disease, stroke)
(Choi, 1988; Lipton and Rosenberg, 1994; Billups et al., 1998).
The diversity o f actions o f L-GLU is to a great extent attributable to a
sophisticated receptor system. Multiple receptor classes for L-GLU, have been identified
and cloned, including both ionotropic and metabotropic receptor families. lonotropic
(ion channel-coupled) L-GLU receptors are named after selective agonists and include:
N-methyl-D-aspartate (NMDA), kainic acid (KA), and a-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid (AMPA) receptors.

These receptors are coupled to both

voltage-dependent and voltage-independent ion channels that gate currents carried by
Na^, K^, and sometimes Ca"^. Unlike the ionotropic KA and AMPA receptors, which are
principally thought to mediate fast excitatory signaling, the ionotropic NMDA receptor
and the metabotropic receptors are involved in the higher order processing required in
development, plasticity, learning, and memory (M onaghan et al., 1989).

The

metabotropic L-GLU receptors (mOluRs) are coupled by guanine nucleotide binding
proteins (G proteins) to intracellular second messenger systems. To date, the mGluR
family comprises eight receptor subtypes that are divided into three groups based on
coupling to second messengers, sequence similarity, and ligand selectivity (Conn and Pin,
1997).

G roup

I

includes m G luR l

and m G luR 5, w hich are coupled to

polyphosphoinositide (PPI) hydrolysis. MGluRs from groups II (mGluR2 and mGluR3)
and III (mGluR4, mGluR6, mGluRV, and mGluRS) are negatively coupled to adenylate
cyclase activity. In addition, a mGluR receptor coupled to phospholipase D has been
identified in the hippocampus (Monaghan et al., 1989).
A lthough L-GLU receptors typically participate in normal physiological
signaling, overactivation of some receptor subtypes can mediate neuronal degeneration.
The ability of L-GLU to damage neurons is specifically referred to as excitotoxicity, a
term coined by J.W. Olney (Olney, 1982). L-Glutamate receptor overactivation occurs
when an agonist, such as glutamate or kainate, is present at the synaptic cleft in elevated
concentrations. L-Glutamate receptor-mediated neurotoxicity is comprised of at least
two components: osmotic-mediated damage and Ca^^-mediated damage (Kiedrowski,
1999). Osmotic-mediated neurotoxicity occurs when excessive levels o f L-GLU produce

a large influx o f Na^ through ionotropic receptors followed by membrane depolarization
and the passive influx o f Cl" and H 2 O. The excessive influx o f ions subsequently leads to
membrane swelling and cell lysis (Dunlop et al., 1999). This type o f neurotoxicity is
typically acute, occurring within minutes o f excitotoxic onset. Conversely, calciummediated neurotoxicity is primarily caused by overactivation of NMDA receptors by LGLU and is marked by gradual cellular disintegration. In normal physiological signaling,
activation of select ionotropic receptors causes membrane depolarization, accompanied
by cation influx (especially Ca^^).

This intracellular Ca^^ then acts as a second

messenger that can modify numerous properties within the postsynaptic cell. Chronic
overactivation o f the NMDA receptor, however, leads to a rapid and persistent increase in
cytoplasmic free Ca^^ (Choi, 1995). This leads to the overactivation o f many Ca"^regulated enzymes (e.g., pro teases, lipases, cyclooxygenases) as well as to the induction
of a number o f pathological schemes, such as free radical production (Choi, 1987;
Castilho et al., 1998). Both osmotic- and Ca^^-mediated neuronal cell deaths have been
reported to occur by necrosis or apoptosis, or a combination of both types o f cell death
(Dunlop et al., 1999). L-Glutamate mediated excitotoxicity involving either osmoticm ediated or Ca^^-mediated cell death, or both, has been im plicated in acute
neuropathologies (e.g., ischem ia and spinal cord traum a), as w ell as chronic
neuropathologies (Huntington’s disease, Amyotropic Lateral Sclerosis (ALS), and
Alzheimer’s disease) (Rothstein et al., 1993; Olney et al., 1997; Roettger and Amara,
1999; Meldrum, 2000; Rowland, 2000).
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The potential for L-GLU to participate in either normal cellular signaling or
pathology suggests that extracellular L-GLU concentrations must be carefully controlled
(Olney et al., 1986; Choi et al., 1987; Headley, 1990). L-Glutamate transporters are
believed to be essential to this regulation.

While L-GLU can act as a substrate of

numerous cellular uptake systems, the specific L-GLU transporters that are thought to
play a primary role in CNS excitatory neurotransmission are referred to as the highaffinity, sodium -dependent transporters.

Efficient removal o f L-GLU from the

extracellular space by high-affinity, Na^-dependent, excitatory amino acid transporters
(EAATs) is postulated to contribute to signal termination, transmitter recycling, and
maintenance o f L-GLU concentrations below those which are excitotoxic (Cotman et al.,
1995; Billups et al., 1998).
The presence o f high-affinity transporter systems for L-GLU in CNS tissue was
first described by Logan and Snyder in 1971 (Logan W.J., 1971). Initially characterized
as both high- and low- affinity uptake components for the accumulation of radiolabelled
amino acid into rat brain synaptosomes, it was subsequently suggested that the highaffinity component may represent a mechanism for the removal o f synaptically released
L-GLU, thereby inactivating L-GLU neurotransmitter activity. In contrast, the lowaffinity uptake component, described as responsible for metabolic trafficking, did not
appear to function in the process o f neurotransmission (Dunlop et al., 1999). Subsequent
studies have demonstrated that Na'^-dependent, high-affinity L-GLU transport occurs in a
sodium-, potassium-, and energy dependent manner, relying on transmembrane ion

gradients from the Na /K pump (Meldrum, 2000). Research has also shown that the ion
gradients used to drive the uptake of L-GLU are necessary to maintain high intracellular
concentrations o f L-GLU.

Under normal conditions, L-GLU concentrations in the

extracellular space range between 0.6 pM and 10 pM , while, estimated intracellular LGLU concentrations in neurons and glial cells are 5-20mM and 0.1-5mM, respectively
(Kuhar and Zarbin, 1978). Thus, EAATs function to maintain intracellular L-GLU
concentrations at 10,000 times the extracellular concentrations (Nicholls, 1990), a
process which can be achieved in milliseconds (Diamond and Jahr, 1997; Grewer et al.,
2000). Consequently, loss o f ion gradient control can lead to an efflux o f L-GLU through
the transporters, increased concentrations o f extracellular L-GLU, and an increased
likelihood o f excitotoxic pathology (Takahashi et al., 1997; Koch et al., 1999).
Similar to the diversity o f the EAA receptor system, evidence indicates highaffinity EAA transport is not mediated by a single transporter system. Existence of
multiple subtypes o f EAATs emerged when kinetic and pharmacological properties of
N a-dependent L-GLU uptake were compared in different cell types or brain regions
(Balcar et al., 1987; Kanai, 1992; Bridges et al., 1999; Fairman and Ameu-a, 1999; Koch
et al., 1999; Brauner-Osborne et al., 2000).

L-Glutamate uptake inhibitors such as

dihydrokainic acid (DHK), L-a-aminoadipic acid (L-a-AA), and L-^ra«.s-2,4-pyrrolidine
dicarboxylate (2,4-PDC) exhibit a variety o f potencies dependent on both regional
specificity and cell types (Bridges et al., 1991).

The existence o f distinct L-GLU

transporters was confirmed by nearly simultaneous isolation o f three cDNAs from non
human species, each encoding a distinct transporter subtype: glutamate/aspartate
transporter (GLAST) (Storck et al., 1992), glutamate transporter-1 (GLT-1) (Pines et al..

1992), and excitatory amino acid carrier 1 (E A A C l) (Kanai, 1992).

The human

homologues o f these were subsequently cloned and named EA A Tl, EAAT2, and EAAT3
(Arriza et al., 1994). Cloning o f the plasma membrane glutamate transporters revealed
that they are members o f a unique family o f molecules separate from the other
neuro transmitter transporters such as GAB A, glycine, noradrenaline, dopamine, and 5hydroxytryptamine. L-Glutamate is recognized as the predominant endogenous substrate
for these transporters, although D- and L- aspartate, as well as a number o f sulfur
containing EAA analogues, can also be translocated by these transporters (Dunlop et al.,
1999). In addition to EAATl (GLAST), EAAT2 (GLT-1), EAATS (EAACl), two more
transporters have been cloned, EAAT4, and EAATS (Arriza et al., 1994; Rothstein et al.,
1994; Fairman, 1995; Gegelashvili and Schousboe, 1998), bringing the total to five.
Although each EAAT subtype has a distinct pharmacology and distribution within the
CNS, they exhibit sequence homology o f 40-65% within species.

When individual

subtypes are compared across species, they demonstrate 90% homology.

Both neurons

and glia are capable o f mediating high-affinity, sodium-dependent L-GLU transport
through the expression o f various EAATs (Gadea and Lopez-Colme, 2001). An essential
step towards understanding the contribution of EAATs to L-GLU-mediated physiology
and pathology is the elucidation o f specific roles and functions o f each transporter
subtype.
R ole o f E A A T s in Synaptic T ransm ission

Although the EAATs are thought to participate in signal termination, transmitter
recycling, and maintenance o f L-GLU concentrations below those, which are excitotoxic,
the relative contribution of each transporter subtype to each o f these roles has not been
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firmly established. Neurotransmitter recycling occurs by the well-described glutamateglutamine cycle.

L-Glutamate is released from synaptic vesicles in the presynaptic

neuron to evoke an excitatory signal in a neighboring neuron. High-affinity, L-GLU
transporters on surrounding astrocytes, then preferentially take up L-GLU, where it is
rapidly converted to glutamine by the glial-specific enzyme, glutamine synthetase
(Alvarez-M aubecin et al., 2000).

A strocytes then release glutam ine and it is

subsequently taken up by neurons and utilized for synthesis o f new L-GLU
(Waagepetersen et al., 2000). This cycle allows for replenishment of L-GLU in neurons,
as these cells lack an anaplerotic pathway for net synthesis o f this neurotransmitter.
Thus, transporter expression in both neurons and astrocytes is critical to normal function
of the EAA system.
The role o f the EAAT system in maintaining L-GLU concentrations below those
that are excitotoxic has become clearer through the utilization of transport inhibitors. Co
adm inistration o f L-GLU with a Na^-dependent uptake inhibitor, P-threo-hydroxy
aspartate, produces greater in vivo pathology than administration of L-GLU alone (Seal
and Amara, 1999). These studies suggest that decreased transporter activity may increase
extracellular L-GLU concentrations, and increase the likelihood of L-GLU-mediated
excitotoxicity. An inverse relationship between excitotoxic damage and EAAT capacity
is also suggested by studies showing that greater concentrations o f L-GLU are required to
produce lesions in vivo than EAA agonists that are non-transportable substrates (Seal and
Amara, 1999). Abnormalities in L-GLU transport are thought to be associated with
specific neuropathologies. Studies have shown that EAAT2 expression is decreased in
the motor cortex and spinal cord of patients with the sporadic form of ALS, leading to
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elevations o f L-GLU in the cerebral spinal fluid (Ye et al., 1999). Additionally, evidence
im plicates the dysregulation o f activity and/or expression o f the EAATs in the
pathogenesis o f several acute neurological diseases, including brain ischemia, brain or
spinal cord trauma, and epilepsy (Dunlop et al., 1999), as well as in slowly progressing
neurodegenerative disorders such as H untington’s chorea and A lzheim er’s disease
(Rothstein et al., 1996; Takahashi et al., 1997; Trotti et al., 1998).
The EAATs are also thought to play an essential role in signal termination.
Studies using electrophysiological methods and transport inhibitors demonstrate altered
postsynaptic signaling in subsets of glutamatergic synapses (Diamond and Jahr, 2000).
Subsequent investigations showed that the transport inhibitors, p-THA and \^-trans-2,APDC, slow AMPA receptor-mediated postsynaptic currents in climbing and parallel fiber
synapses o f cerebellar Purkinje neurons, suggesting they affect the speed of clearance of
transmitter.

However, these inhibitors showed no measurable effect in modulating

postsynaptic response kinetics in other glutamatergic synapses in the cerebellum and
hippocampus (Sarantis et al., 1993; Bridges et al., 1999). Thus, the development of novel
selective inhibitors may further elucidate whether the distinct EAAT subtypes can
influence the strength o f excitatory signaling by modulating concentration and/or time
course o f L-GLU at individual synapses (Bridges et al., 1999). Additional roles for the
EAATs in excitatory signaling have been suggested: 1) transport may lim it
desensitization o f postsynaptic receptors, 2) uptake may limit the diffusion of L-GLU
thus preventing “spill-over” and unwanted activation o f L-GLU receptors, and 3)
transport may play a role in maintaining a high specificity o f synaptic transmission by
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limiting the extent o f cross talk between neighboring synapses (Rothstein et al., 1996;
Dunlop et al., 1999).
D istribution o f L -G lutam ate T ransporters

Cloning o f the EAATs in the early 1990’s enabled the production of sequencespecific molecular probes (cDNA and oligo probes, and antipeptide antibodies) to
elucidate the distribution o f individual transporters and corresponding mRNA
(G egelashvili and Schousboe, 1998). These probes have dem onstrated that
GL AST/E A AT 1 is abundant in the CNS, as well as in peripheral tissues, such as heart,
muscle, placenta, lung, liver, testes, and retina in several species (Furness and Lehre,
1997; Gegelashvili and Schousboe, 1998; Seal and Amara, 1999).

GLT-1/EAAT2

mRNA localizes to the CNS o f human and rodent, with low levels o f expression in
placenta. EAACl/EAAT3 mRNA is abundant in the CNS, although it has also been
detected in kidney, heart, muscle, lung, placenta, and liver (Gegelashvili and Schousboe,
1998). While GLAST/EAAT 1 and EAAC1/EAAT3 demonstrate significant distribution
in peripheral tissues, GLT-1/EAAT2 is thought to be more specific to the CNS (Rothstein
et al., 1994). The more recently cloned transporter, EAAT4 (Fairman, 1995) is found
predominantly in the CNS with some expression observed in the placenta (Gegelashvili
and Schousboe, 1998) while, the most recently identified transporter, EAAT5 (Arriza et
al., 1997) localizes to the retina (Danbolt et al., 1998; Eliasof et al., 1998; Vandenberg,
1998).
Regional distribution studies within the CNS demonstrate that the cerebellum is
specifically enriched with GLAST/EAATl, with lower expression levels in the forebrain
and the olfactory bulb (Rothstein et al., 1994). High expression levels o f GLT-1/EAAT2
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mRNA are detected in hippocampus, cerebral cortex, thalamus, and striatum, with lower
expression observed in brain stem, spinal cord, cerebellum, and olfactory bulb (Rothstein
et al., 1994). Localization studies of EAACl/EAAT3 demonstrate high expression levels
in cerebral cortex, caudate-putamen, hippocampus, and olfactory bulb, with lower levels
in spinal cord and cerebellum (Rothstein et al., 1994).

High levels o f EAAT4 are

localized in the cerebellum, particularly in the Purkinje cell layer, with low levels of
expression in other forebrain regions including hippocampus and cortex (Furuta et al.,
1997).
Considerable research has been devoted to the cellular localization o f L-GLU
transporters both in vivo and in vitro (Gegelashvili and Schousboe, 1998; Seal and
Amara, 1999). It is now generally accepted that GLAST/EAATl is the most abundant
transporter in the cerebellum and is expressed in both glial cells and in neurons. Initial
cloning experim ents revealed GLAST/EAATl protein expression predominantly
localized to astrocytes (Arriza et al., 1994). However, reports have since shown that
GLAST/EAATl mRNA and protein localizes to various neuronal cell types including
cerebellar granule neurons, rat cochlear hair cells, and neuronal cell lines (Rothstein et
al., 1994).

GLT-1/EAAT2 primarily localizes to astrocytes, thus G LT-l/EA A T2’s

designation as the “glial glutamate transporter”. Initial studies reported GLT-1/EAAT2
protein exclusively in rat astrocytes (Danbolt et al., 1998) however, GLT-1/EAAT2
mRNA has been found in vitro in cultures o f rat astrocytes, m icroglia and
oligodendrocytes. Additionally, GLT-1/EAAT2 shows some, although limited neuronal
expression, GLT-1 mRNA had been found in a subset of hippocampal neurons (Torp et
al., 1994).

Despite EAACl/EAAT3 being commonly referred to as the “neuronal
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glutamate transporter”, EAACl/EAAT3 protein has been found in the rat C6 glioma cell
line and several human tumors o f glial origin (Kanai, 1992; Kanai et al., 1994a; Rothstein
et al., 1994; Vandenberg, 1998). Within the CNS, BAAT4 is expressed predominantly in
Purkinje cell layer neurons (Vandenberg, 1998). Finally, EAAT5 localizes to the retina
with specific cellular localization yet to be determined (Arriza et al., 1994).
Studies examining the subcellular distribution of the EAATs have provided great
insight into the functional significance o f different subtypes of high affinity L-GLU
transporters. GLAST/EAATl and GLT-1/EAAT2 proteins are situated in the plasma
membrane o f neurons and glial cells, with highest transporter density in the thin
processes where transporters colocalize and likely couple functionally with glutamine
synthetase (D erouiche and Rauen, 1995; G egelashvili and Schousboe, 1998).
Interestingly, GLT-1/EAAT2 is not expressed uniformly in astrocyte membranes. More
GLT-1/EAAT2 protein is present in those portions o f glial cell membranes that face
nerve terminals, axons, and dendritic spines (Takahashi et al., 1997). These findings are
consistent with the hypothesis that glial glutamate transporter uptake functions to
maintain L-GLU concentration below neurotoxic levels (Takahashi et al., 1997).
Neuronal L-GLU uptake is conventionally thought to occur in presynaptic terminals,
where it terminates the synaptic action o f L-GLU and recycles the transmitter into
synaptic vesicles for re-use (Yamada et al., 1996). However, EAAC1/EAAT3 expression
has been found throughout the soma and dendritic tree o f Purkinje cells (Rothstein et al.,
1994) and further studies have demonstrated EA ACl/EA A T3 immunoreactivity in
presynaptic boutons o f GABAergic neurons (Gegelashvili and Schousboe, 1998). Tissue
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distribution, CNS distribution, cellular distribution, and developmental expression
patterns o f the L-GLU transporter subtypes are summarized in Table 1.
A differential function for GLAST/EAATl and GLT-1/EAAT2, compared to
EAAC1/EAAT3 is suggested by experiments in which molecular biological methods
were used to prevent transporter expression (Rothstein et ah, 1996).

Deleting

G LAST/EAATl and GLT-1/EAAT2 led to a general rise o f extracellular L-GLU
concentrations, which induced neuronal cell death (Rothstein et ah, 1994). In contrast,
loss o f EAACl/EA A T3 was reported to not produce a rise in extracellular L-GLU
concentrations (Gegelashvili and Schousboe, 1998). Further studies are needed to clarify
not only the roles o f these three transporters but also the roles of EAAT4 and EAATS.
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Table 1. Distribution of Glutamate Transporters
MAMMALIAN
TISSUE
DISTRIBUTION

REGIONAL
DISTRIBUTION
WITHIN THE CNS

CELLULAR
DISTRIBUTION

CNS
Skeletal Muscle
Liver
Lung
Placenta

Cerebellum
Forebrain
Olfactory Bulb

Neurons

CNS
Placenta
Pineal Gland
Retina

Cerebral Cortex
Hippocampus
Thalamus
Spinal Cord
Cerebellum

EAACl V
EAAT3^

CNS
Intestine
Kidney
Liver
Heart
Placenta

Cerebellum
Hippocampus
Olfactory Bulb
Spinal Cord
Caudate Putamen

Neurons

Decreases during
development^

EAAT4^

CNS
Placenta

Cerebellum
Hippocampus
Cerebral Cortex

Neurons
- Granule
- Purkinje

Increases during
development^

TRANSPORTER
SUBTYPE

GLASTV
EAAT F

GLT-17
EAAT2^

DEVELOPMENTAL
EXPRESSION
PATTERNS
Increases during
development^

Astrocytes
- Bergmann Glia
Neurons
- limited

Increases during
development^

Astrocytes

maybe
Astrocytes
EAAT5^

Retina

??

??
_________

(Storck et al., 1992)
(A rriza et al., 1994)
(B ar-Peled et al., 1997)
(Pines et al., 1992)
(K anai, 1992)
(Fairm an, 1995)
(E liasof et al., 1998)
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R egulation o f T ransporter E xpression

Recent evidence that EAAT expression is a developmentally regulated process
has emerged from studies utilizing mouse and rat CNS and spinal cord tissue (Sutherland
et al., 1996; Furuta et al., 1997). Prenatally, GLAST expression predominates, with very
low levels of GLT-1 in evidence (Bar-Peled et al., 1997). Postnatally, both GLAST and
GLT-1 increase dramatically during periods corresponding to synaptogenesis. Similar
changes in EAAT 1-4 expression have recently been described in human brain during
development (Bar-Peled et al., 1997).
Primary dissociated CNS cultures remain a useful tool for the investigation of
EAAT expression and neurotransmitter uptake and metabolism by different cell types
during development (Reynolds and Herschkowitz, 1987). However, in vitro culture
systems must be used with some caution.

Various in vitro culture systems exhibit

different patterns o f EAAT expression from those found in vivo, indicating growth
conditions may influence EAAT expression. For example, cultured astrocytes do not
exhibit the same high levels of expression of the GLT-1/EAAT2 subtype, characteristic
of adult brain (Gegelashvili et al., 1997). Manipulating astrocyte cultures has also been
shown to alter EAAT expression patterns. Exposure to neuron-conditioned medium
(Gegelashvili and Schousboe, 1997a), co-culture with neurons (Swanson et al., 1997),
and exposure to dibutyryl cAMP (Schlag et al., 1998) all result in a dramatic upregulation
o f EAAT2 expression in astrocytes. Studies demonstrating changes in EAAT expression
raise the possibility o f identifying factors, which may increase or decrease EAAT
expression both in vivo and in vitro, providing insight into transporter abnormalities and
alterations during disease states and also as potential therapeutic targets.
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Specific A im s

The purpose o f the present work is to obtain fundamental information about
EAAT distribution in primary cell cultures as a tool for evaluating the roles of the
EAATs, particularly as related to excitotoxicity.

Before a clear understanding of

transporter function can be attained, it is necessary to determine EAAT distribution
patterns and expression levels. Therefore, this project will define the cellular distribution
o f the excitatory amino acid transporters, GLAST, GLT-1, EA A C l, and EAAT4, in
cerebellar granule neuron (CGN) cultures.

Additionally, this project will examine

changes in EAAT expression associated with the presence o f glial cells. The glial celldepleted population is greater than 90% homogenous, containing predominantly CGNs
(Schousboe et al., 1985; Schousboe et al., 1989). In contrast, the glial cell-enriched
populations (mixed neuron/glial cell cultures) are heterogeneous, containing not only
CGNs, but also astrocytes and a few oligodendrocytes (Campbell and Shank, 1978).
Cerebellar granule neurons were chosen for the following reasons: 1) CGNs are
glutamatergic neurons (Drejer et al., 1983a), 2) CGNs can be grown in the presence or
absence o f astrocytes, unlike other primary neuronal cultures, and 3) they are an often
used model in L-GLU-mediated excitotoxicity studies. The specific aims of this study
can be summarized by the following questions:
1) What is the cellular distribution o f GLAST, GLT-1, EA A C l, and EAAT4 in
primary cultures of rat cerebellar granule neurons?
2) Does the presence o f glial cells alter the expression patterns o f GLAST, GLT-1,
EA A C l, and EAAT4 in primary cultures of rat cerebellar granule neurons?
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These studies will improve the current understanding o f the distribution o f the
glutamate transporters in primary rat CGN cultures. This investigation will also provide
further understanding o f the role that glial cells play in influencing EAAT expression
patterns in neurons. Finally, this study will provide a needed data base for future studies
on L-GLU transporters, particularly as related to regulation of expression, functional
studies, developmental expression, and glutamate excitotoxicity. Future studies will aim
to better understand the influence o f astrocytes on neuronal EAAT expression and to
utilize molecular methods to gain insight into how tremsporter expression patterns change
with altered conditions, as can happen in pathological situations.
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MATERIALS AND METHODS
T issue C ulture

Primary cultures of rat cerebellar granule neurons (CGNs) and mixed CGN/glial
cell cultures were prepared essentially as previously described (Schousboe et al., 1989).
All animal procedures were in strict accordance with NTH Guide for the Care and Use of
Laboratory Animals and were approved by the University o f Montana AAALAC Animal
Care Committee. Briefly, cerebellar tissue was aseptically removed from 7-day-old rat
pups obtained from timed pregnant Sprague Dawley rats (Simonsen Laboratories, Gilroy,
CA). The day o f birth was designated as postnatal day 0 (PO). Both culture types were
prepared by a similar protocol, except that glial proliferation in CGN cultures was
suppressed by adding cytosine arabinoside (20p.M) 24 hours after plating.

This

procedure kept the number o f non-neuronal cells below 5% (Schousboe et al., 1989).
Cerebellar tissue was dissected free from the meninges, transferred to a beaker containing
10ml Krebs buffer (120mM NaCl, 5mM KCl, 1.2mM KH 2 PO 4 , 1.2mM MgS 0 4 , 25mM
NaHCOs, 13mM glucose, and 0.3% bovine serum albumin, pH 7.4, equilibrated with
atmospheric air/CO:), and minced with sterile dissecting scissors. Minced tissue was
transferred to a sterile 50ml tube, triturated with a Pasteur pipette, and centrifuged (3 min
200 X g) at room temperature. Cells were dissociated by trypsinization (Type IX, Sigma,
0.025% (w/v) in Krebs buffer, 15 min., 37° C). Immediately after the incubation, 20ml
of Krebs buffer containing 0.004% (w/v) DNase I (Sigma) and 0.03% (w/v) soybean
trypsin inhibitor (Type I-S, Sigma) was added to halt proteolytic activity. The mixture
was centrifuged for 5 min at 200 x g; subsequently, the supernatant was removed and
discarded. The pellet was resuspended in the presence o f DNase I (0.004% (w/v) in

19

Krebs buffer) and soybean trypsin inhibitor (0.003% (w/v) in Krebs buffer) followed by
trituration. The cell suspension was left in the hood to allow sedimentation to occur. The
supernatant, containing dissociated cells, was resuspended in 3ml o f Eagle’s Minimum
Essential Medium (EMEM, GibcoBrl). Media was supplemented to contain 24.5mM
KCl, 30mM glucose, 7pM para-aminobenzoic acid, 100 mU/liter insulin, 10% fetal calf
serum, (GibcoBrl), and 1 % antibiotic-antim ycotic (GibcoBRl), then sterilized by
filtration (.22|iM , Corning), and equilibrated with atmospheric air/CO 2 at 37° C
(modified EMEM). The suspended cells were centrifuged for 5 min at 200 x g, the
supernatant was discarded, and the pellet was resuspended in 10ml culture media
(modified EMEM). Twenty-four hours prior to cell seeding, tissue culture plates (12well, 3.8cm^, Costar) were prepared by inserting a round glass coverslips (18mm, VWR
Scientific) in each well, coating the coverslips with poly-L-lysine (O.IM, Sigma), and
allowing plates to sit in the tissue culture hood before rinsing £ind cell seeding. Cells were
then seeded (1.0 x 10^ cells/well) on the poly-L-lysine coated glass coverslips in 2 ml of
culture media and allowed to grow for 10 days.

C ulture M aintenance and Im m unocytochem istry Pretreatm ent

Twenty-four hours after seeding, 12-well plates were treated, where indicated,
with 20pM cytosine arabinoside (Sigma, St. Louis, MO) to halt proliferation of non
neuronal cell types. Tissue culture media was changed every third day, and the cells
were fixed at 10 days in vitro (10 DIV) with 4% paraformaldehyde in 0.1 M phosphatebuffered saline (pH 7.4) for 20 minutes. Fixative was aspirated, replaced with storage
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buffer (O.IM PBS, pH 7.4), and cells were stored at 4°C until processed.

All

immunostaining took place with in 5 days of fixation.

A ntibodies

Four different subtype-specific antipeptide antibodies to glutamate transporters
were used in this study. These rabbit polyclonal antibodies recognize distinct proteins for
GLAST (543 amino acids; C-terminal), GLT-1 (573 amino acids; C-terminal), EAACl
(523 amino acids; C-terminal), and EAAT4 (561 amino acids; C-terminal) (Alpha
Diagnostics). Monoclonal antibodies to neurofilament (RMO270; NF; courtesy of Dr.
Virginia Lee, Philadelphia, PA) and neuronal nuclei (NeuN, Chemicon, Temecula, CA)
were used as markers for neuronal cytoskeleton and neuron specific nuclear protein,
respectively.

A monoclonal antibody against glial fibrillary acidic protein (GFAP,

Chemicon) was used as a marker for astrocytes.

Single L ab el Im m unocytochem istry

Plates were removed from storage, rinsed twice with O.IM PBS, and blocked with
either 5% normal horse sera (NHS, Vector Laboratories, Burlingame, CA) or 5% normal
goat sera (NGS, Vector Laboratories) in O.IM PBS for 10 min.

Cells were then

permeabilized with 1% Triton X-100 in O.IM PBS for 10 min. A second 20-minute
block with 5% NHS or 5% NGS, respectively, followed the permeabilization step. Cells
were then immunostained using primary antibodies against one o f the following: NF
(1:100), NeuN (1:100), GFAP (1:100), GLAST (1:100), GLT-1 (1:100), EAACl (1:100),
or EAAT4 (1:100). Both primary and secondary antibodies were diluted in O.IM Tris
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buffer solution containing 0.01% sodium Azide and 0.1% Bovine serum albumin (TAB).
Primary antibody was added to the appropriate well, and incubated for 2 hours at 37°C.
Primary antibodies were detected with the appropriate secondary antibody, FITCconjugated horse anti-mouse (1:100; Vector Laboratories) or Cy3-conjugated goat anti
rabbit (1:800; Jackson ImmunoResearch, W est Grove, PA), for 1 hour at room
temperature.

Cells were rinsed twice with O.IM PBS, once with deionized water,

coverslipped with Vectashield (Vector Laboratories), and stored at 4°C in the dark. For
no-primary antibody controls, wells were treated in the same manner as experimental
wells except control cells were incubated with secondary antibody alone.

D ouble L abel Im m unocytochem istry

Plates were removed from storage, rinsed twice with O.IM PBS, then blocked
with both 5% NHS and 5% NOS in O.IM PBS for 10 min. Cells were then permeabilized
with 1% Triton X-100 in O.IM PBS for 10 min. A second 20-minute block with both 5%
NHS and 5% NGS followed the permeabilization step. Cells were then immunostained
using primary monoclonal antibody against either NF (1:100) or NeuN (1:100) or GFAP
(1:100) diluted in TAB, and added to the appropriate well. Cells were incubated in
primary antibody for 2 hours at 37°C. Primary monoclonal antibodies were detected with
secondary antibody, FITC-conjugated horse anti-mouse (1:100; Vector Laboratories), for
1 hour at room temperature. Cells were rinsed twice with O.IM PBS. Cells were then
immunostained using primary polyclonal antibody GLAST (1:100), GLT-1 (1:100),
EA ACl (1:100), or EAAT4 (1:100) diluted in TAB, and added to the appropriate well.
Cells were incubated in primary antibody for 2 hours at 37°C. Primary polyclonal
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antibody was detected with secondary antibody, Cy3-conjugated goat anti-rabbit (1:800;
Jackson ImmunoResearch) for 1 hour at room temperature. Cells were rinsed twice with
O.IM PBS, once with deionized water, coverslipped with Vectashield, and stored at 4°C
in the dark.

For no-primary antibody controls, wells were treated the same way as

experimental wells except control cells were incubated with both secondary antibodies
alone.

Im m u nocytoch em ical A nalysis

All observations are based on a minimum N = 5, where N is the number of
different tissue culture preparations. Within each preparation, at least 2 different culture
plates were immunostained for the same transporters. Additionally, staining was done in
duplicate by staining adjacent wells within each plate.
Microscope slides were viewed with a Nikon E-800 fluorescent microscope at
magnifications ranging from 4-40X.

Representative photographs were taken using

Kodak Color Chrome Elite slide film (ASA 200) in a Nikon FX-35A camera. Slides
were scanned into a Macintosh G4 computer using a Nikon Coolscan 4000 slide scanner
and Nikon Scan 3.1 image analysis software. Adobe Photoshop 5.5 image analysis
software was used to merge images into double labels.

Additionally, some microscope

slides were viewed w ith a Bio-Rad Radiance 2000 MP laser scanning confocal
microscope. Representative photographs were taken using a Bio-Rad radiance 2000 MP
multi-photon imaging system and viewed on a Dell Power Edge 1300 computer using
LaserSharp 2000 software.
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RESULTS
C ell C ulture D escription —C ell Type Determ ination

Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures
prepared

from

7-day old rats w ere characterized by immunocytochemistry.

Immuno reactivity for neuro filament (NF) and neuronal nuclei (NeuN) were used to
identify neurons, while astrocytes were identified by immunoreactivity for glial fibrillary
acidic protein (GFAP). Cerebellar granule neuron cultures contain small granule neurons
(6-9 um) which typically grow into large aggregates containing numerous cell bodies
(Fig. 2C, arrows) with neuronal processes extending from the clusters of cell bodies (Fig.
2A, arrows) (Schousboe et al., 1989). Although, replication o f non-neuronal cells was
halted by the addition o f cytosine arabinoside in these cultures, a small number of
astrocytes can remain. These astrocytes were rarely observed, however Fig. 2E (arrows)
shows an example o f astrocytes present in CGN cultures. Mixed CGN/glial cell cultures,
in which cytosine arabinoside was not added, contain many neurons, as well as astrocytes
(Fig. 2F, arrows). Although many astrocytes are present in this culture type, the neurons
still grow as characteristic clusters o f cell bodies (Fig. 2D, arrows) with numerous
processes projecting outward (Fig, 2B, arrows). In both culture types, neuronal clusters,
as well as astrocytes appeared to be viable and healthy (based on trypan blue exclusion;
results not shown) with intact cell bodies and many long processes.

Cell C ulture D escription - L-Glutamate Transporter Expression

To investigate w hether the two culture types (CGN cultures and mixed
CGN/glial) contain the glutamate transporters, GLAST, GLT-1, EA A C l, and EAAT4,
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subtype specific antibodies are used to label the transporters. Both culture types contain
various cells that are immunopositive for the glutamate transporters, GLAST, GLT-1,
EA A C l, and EAAT4.
Both CGN cultures and m ixed CGN/glial cell cultures are positively
immunoreactive for GLAST.

Punctate, intense, labeling o f GLAST is observed on

filaments in both culture types, presumably neuronal filaments as judged by morphology
(Fig. 3A and 4A, arrows). Positive GLAST immunoreactivity in clusters o f cell bodies is
also observed in both culture types (Fig. 3A and 4A, arrows).

Clusters of cell bodies

seen in CGN cultures (Fig. 3A, arrows) and in mixed CGN/glial cell cultures (Fig. 4A,
arrows) are moderately labeled for GLAST. These clusters of cells are characteristic of
cerebellar granule neurons grown in culture, as described in previous studies (Schousboe
et al., 1985; Schousboe et al., 1989). Additionally, the size of these cells is consistent
with being granule neurons (Schousboe et al., 1985; Schousboe et al., 1989) as well as
the staining pattern (positive NeuN and NF immunoreactivity).
Immunostaining patterns for GLT-1 differs slightly between CGN cultures and
mixed CGN/glial cell cultures. Although, there are many neuronal filaments in both
culture types, the number of GLT-1 positive filaments slightly increases in CGN cultures
(Fig. 3B, arrows) compared to the mixed CGN/glial cell cultures (Fig. 4B, arrows). From
the staining patterns, it was quite apparent that NF staining was similar between these
two culture types. Thus, the changes in GLT-1 immunoreactivity between cultures may
not be attributable to changes in the number o f neurofîlaments, but rather to differences
in GLT-1 immunoreactivity on these filaments. Moderate labeling o f the clusters of cell
bodies is similar in both culture systems (Fig. 3B and 4B, arrows).
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Intense labeling o f EAACl is observed in clusters o f cell bodies in both CGN
(Fig. 3C, arrows) and mixed CGN/glial cell cultures (Fig. 4C, arrows).

From the

staining, we could see that there was not a differential EAACl pattern o f expression
between these two culture types.
Im m unostaining o f EAAT4 in both types o f cultures exhibit different
morphological patterns than those observed for all other EAATs on filaments. While
filam ents that are immunostained for GLAST, GLT-1, and EA ACl are linear and
typically connected clusters o f cells, the EAAT4 positive filaments display a stellate
appearance and are morphologically similar to astrocytic filaments (Fig. 3D and 4D). In
addition, the number o f EAAT4 positive cells varies between the two culture types. In
CGN cultures, EAAT4 is expressed on a limited number o f cells (Fig. 3D), while in
mixed CGN/glial cell cultures (Fig. 4D), EAAT4 is expressed on numerous cells, as is
expected if these filaments are indeed astrocytic filaments. Immunoreactivity of EAAT4
on clusters o f cell bodies is observed within both culture types (Fig. 3D and 4D). These
cells display characteristic clumping typical of CGNs grown in vitro. Localization of the
L-GLU transporter subtypes in both CGN cultures and mixed CGN/glial cell cultures is
summarized in Table 2.

26

Table 2. Cellular Distribution of Glutamate Transporters In Cerebellar
Cell Cultures

GLAST

G L T -1

EAACl

EAAT4

Neurons

Neurons

Neurons

Neurons

C G N
C u ltu r e s

M

ix e d

Astrocytes
-Few

Astrocytes
-Few

Neurons

Neurons

Neurons

Neurons

C G N /g lia l
C e ll
C u ltu r e s

Astrocytes
-Many

Astrocytes
-Many
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Fig. 2. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures are
immunostained for neurofilament (NF), neuronal nuclei (NeuN), and glial fibrillary
acidic protein (GFAP) (green) (10 DIV).

A) CGN cultures immunostained for NF. B)

Mixed CGN/glial cell cultures immunostained for NF. C) CGN cultures immuno stained
for NeuN.

D) Mixed CGN/glial cell cultures immunostained for NeuN. E) CGN

cultures immunostained for GFAP. F) Mixed CGN/glial cell cultures immunostained for
GFAP. Immuno staining demonstrates that both types o f primary cell cultures contain
neurons with numerous filaments extending from clusters o f cell bodies. Although
GFAP positive astrocytes are not generally observed in CGN cultures. Fig. 2E is
representative o f those astrocytes present in CGN cultures.

Numerous astrocytic

filaments are observed in the mixed CGN/glial cell cultures. Mag Bar=50

|Lim
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Fig.

3. Cerebellar granule neuron (CGN) cultures immunostained for the excitatory

amino acid transporters (red), GLAST, GLT-1, EAACl, and EAAT4 (10 DIV).
A) CGN cultures immunostained for GLAST. B) CGN cultures immunostained for
GLT-1.

C)

CGN cultures imm unostained for E A A C l.

D)

CGN cultures

immunostained for EAAT4. Immunostaining exhibits the presence o f the four glutamate
transporters in this culture system. While the four transporters are present, they clearly
have distinct expression patterns within this primary cell culture type. GLAST is mainly
expressed on straight filaments, GLT-1 is found in both filaments and clusters of cell
bodies. EAACl is predominantly found on clusters o f cell bodies, and EAAT4 localizes
to fibers with a stellate morphology. Mag Bar=50 pm
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Fig.

4.

M ixed cerebellar granule neuron/glial cell cultures (mixed CGN/glial)

im m unostained for the excitatory amino acid transporters (red), GLAST, GLT-1,
E A A C l, and EAAT4 (10 DIV). A) Mixed CGN/glial cell cultures immunostained for
GLAST. B) Mixed CGN/glial cell cultures immunostained for GLT-1. C) Mixed
CGN/glial cell cultures immunostained for EAACL D) Mixed CGN/glial cell cultures
immunostained for EAAT4. While the four transporters are present, they have distinct
patterns o f expression within this primary cell culture type. GLAST is mainly expressed
on filaments, with moderate expression on clusters o f cell bodies. GLT-1 is found in
both filaments and clusters o f cell bodies. EAACl is found on clusters of cell bodies
with limited expression in filaments. EAAT4 localizes to numerous fibers with a stellate
morphology. Mag Bar=50 pm
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D ouble L ab elin g o f C G N C ultures and M ixed C G N /G lial C ell C ultures

To confirm transporter location on distinct cell types, dual-label experiments were
used to probe the cultures for cell type (neurons, NF or NeuN and astrocytes, GFAP) and
transporter subtype (GLAST, GLT-1, EA A Cl, EAAT4) expression. Utilization o f the
neuronal markers, NF and NeuN, allow for further delineation o f transporter localization
on either neuronal processes or neuronal cell bodies.

Identification o f GLAST P ositive Cells

Double labeling CGN cultures and mixed CGN/glial cell cultures with GLAST
(red) and either NF, NeuN, or GFAP, (green) demonstrate that GLAST is expressed by
both neurons and astrocytes. Neuronal processes are positively immunoreactive for
GLAST in both CGN cultures (Fig. 5A, arrows) and in mixed CGN/glial cell cultures
(Fig. 5D, arrows). Neuronal cell bodies also express GLAST in both culture types (Fig.
5B and 5E, arrows). In general, there are few astrocytes present in CGN cultures, yet
weak expression of GLAST is seen on a few of the remaining astrocytic filaments (Fig.
5C). While numerous astrocytic filaments appear to be GLAST positive in the mixed
cultures (Fig. 5F).

Identification o f GLT-1 P ositive Cells

Double labeling CGN cultures and mixed CGN/glial cell cultures with GLT-1
(red) and either NF, NeuN, or GFAP (green) demonstrates that GLT-1 is expressed by
neurons, but not astrocytes. GLT-1 expression is evident on neuronal filaments in both
cultures (Fig. 6A and 6D). Neuronal filaments that express GLT-1 are more numerous in
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the CGN cultures than in the mixed CGN/glial cell cultures (Fig, 6A and 6D) and again
this is not attributable to fewer filaments present in the mixed CGN/glial cell cultures.
Intense GLT-1 expression is exhibited on neuronal cell bodies in both culture types (Fig.
6B and 6E). GLT-1 expression by astrocytes is not observed in either culture type (Fig.
6C and 6F), although neuronal filaments expressing GLT-1 do lie in close proximity to
astrocytic filaments.

Identification o f E A A C l P ositive Cells

Double labeling cell cultures with EAACl (red) and either NF, NeuN, or GFAP
(green) demonstrates that EAACl is only expressed in neurons.

While little to no

expression o f EAACl is observed on the neuronal filaments in both culture types (Fig.
7A and 7D), intense EAACl expression is evident on neuronal cell bodies (Fig. 7B and
7E). EAACl does not co-localize with GFAP positive astrocytes in either culture type
(Fig. 1C and 7F).

Identification ofE A A T4 P ositive Cells

Double labeling CGN cultures and mixed CGN/glial cell cultures with EAAT4
(red) and either NF, NeuN, or GFAP (green) demonstrates that EAAT4 is predominantly
expressed in astrocytes, although some expression is observed in neurons. EAAT4
expression is not present on neuronal filaments (Fig. 8A and 8D) but localizes to
neuronal cell bodies (Fig. 8B and 8E).

EAAT4 expression is mainly observed in

astrocytes as shown by occasional co-localization with GFAP positive filaments in CGN
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cultures (Fig. 8C) and numerous GFAP positive astrocytes in mixed CGN/glial cell
cultures (Fig. 8F).
Confocal laser scanning microscopy with a highly sensitive fluorescence signal
am plification system was used to visualize the distribution o f L-GLU transporter
immunoreactivity more clearly. This technique is used to confirm cell type specific,
GLAST, GLT-1, EAACl and EAAT4 transporter localization. These results show that
GLAST, GLT-1, EAACl and EAAT4 are expressed by granule neurons (Fig. 9). Neither
GLT-1 (Fig. lOB) nor EAACl (Fig. IOC) display astrocytic expression, however, both
GLAST (Fig. 10A) and EAAT4 (Fig. lOD) are localized to cerebellar astrocytes present
in

b o th

CGN

c u ltu r e s

an d

m ix e d

C G N /g lia l

c e ll

c u ltu re s .
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Fig. 5. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures are
dual-labeled for the glutamate transporter, GLAST (red), and one o f the cell-type
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV).
A) CGN cultures immunostained for GLAST and NF. B) CGN cultures immunostained
for GLAST and NeuN. C) CGN cultures immunostained for GLAST and GFAP. D)
Mixed CGN/glial cultures immunostained for GLAST and NF. E) Mixed CGN/glial
cultures im m unostained for GLAST and NeuN.

F)

M ixed CGN/glial cultures

immunostained for GLAST and GFAP. Staining indicates that GLAST expression
patterns do not vary widely between these two culture types. In both cultures GLAST is
localized to neurons, both on the neuronal filaments and on the clusters o f cell bodies.
GLAST is also found on astrocytes in both culture types. Mag Bar=50 |xm

38

39

Fig. 6. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures
double labeled for the glutamate transporter, GLT-1 (red), and one o f the cell-type
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV).
A) CGN cultures immunostained for GLT-1 and NF. B) CGN cultures immuno stained
for GLT-1 and NeuN. C) CGN cultures immunostained for GLT-1 and GFAP. D)
Mixed CGN/glial cell cultures immunostained for GLT-1 and NF. E) Mixed CGN/glial
cell cultures immunostained for GLT-1 and NeuN. F) Mixed CGN/glial cell cultures
immunostained for GLT-1 and GFAP. Immunostaining shows that neurons do express
GLT-1. Immunoreactivity on neuronal clusters is similar in both culture types; however,
more neuronal filaments in the CGN cultures are labeled for GLT-1 than the neuronal
filaments in mixed CGN/glial cell cultures. Astrocytes do not appear to express GLT-1
in either culture type, although GFAP positive filaments are sometimes found in close
proximity to GLT positive filaments. Mag Bar=50

|L im

40

&

41

Fig. 7. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures
dual-labeled for the glutamate transporter, EA ACl (red), and one o f the cell-type
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV).
A) CGN cultures immunostained for EAACl and NF. B) CGN cultures immunostained
for EA A Cl and NeuN. C) CGN cultures immunostained for EAACl and GFAP. D)
Mixed CGN/glial cell cultures immunostained for EAACl and NF. E) Mixed CGN/glial
cell cultures immunostained for EAACl and NeuN. F) Mixed CGN/glial cell cultures
immuno stained for EAACl and GFAP. Clusters o f neuronal cell bodies are strongly
imm unopositive for E A A C l, while neuronal filaments only exhibit weak, if any,
expression o f EAACl in both culture types. Co-localization o f EAACl and GFAP is not
observed, suggesting astrocytes in these culture types do not express EA ACl.
Bar=50 |im

Mag
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Fig. 8. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures are
dual-labeled for the glutamate transporter, EAAT4 (red), and one o f the cell-type
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV).
A) CGN cultures immunostained for EAAT4 and NF. B) CGN cultures immunostained
for EAAT4 and NeuN. C) CGN cultures immunostained for EAAT4 and GFAP. D)
Mixed CGN/glial cell cultures immunostained for EAAT4 and NF. E) Mixed CGN/glial
cell cultures immunostained for EAAT4 and NeuN. F) Mixed CGN/glial cell cultures
immunostained for EAAT4 and GFAP. Neuronal filaments are not immunopositive for
EAAT4, although clusters of neuronal cell bodies do moderately express EAAT4 in both
culture systems. The few remaining astrocytes present in CGN cultures as well as the
numerous astrocytes present in the mixed CGN/glial cell cultures are intensely
immunopositive for EAAT4. Mag Bar=50 jim
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Fig. 9.

Confocal images o f cerebellar granule neuron (CGN) cultures double labeled

for NeuN (green) and one o f the glutamate transporters (red), GLAST, or GLT-1, or
E A AC 1, or EAAT4 (10 DIV). A) CGN cultures immunostained for NeuN and GLAST.
B)

CGN cultures im m unostained for NeuN and GLT-1.

C)

CGN cultures

immunostained for NeuN and E A AC 1. D) CGN cultures immunostained for NeuN and
EAAT4. The four glutamate transporters, GLAST, GLT-1, EA AC 1, and EAAT4 do colocalize with NeuN, confirming that granule neurons express these transporters. Mag
Bar=50 pm
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Fig.

10.

Laser scanning confocal microscopy images o f cerebellar granule neuron

(CGN) cultures double labeled for GFAP (green) and one o f the glutamate transporters,
GLAST, or GLT-1, or E A A C l, or EAAT4 (red) (10 DIV). A) CGN cultures
immunostained for GFAP and GLAST. B) CGN cultures immunostained for GFAP and
GLT-1. C) CGN cultures immunostained for GFAP and EAACL D) CGN cultures
immunostained for GFAP and EAAT4. GLAST and EAAT4 demonstrate co-localization
with GFAP, while no co-localization was observed with GLT-1 or EAACl and GFAP.
Mag Bar=50 pm
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DISCUSSION
The existence o f multiple excitatory amino acid transporter (EAAT) subtypes
raises the possibility that EAATs play a variety of roles in the central nervous system
(CNS). Studying the expression patterns of L-GLU transporter subtypes is an important
approach for elucidating the potential for distinct EAAT contributions to excitatory
signaling, metabolic regulation, or excitotoxic protection. Major advances in the field
came with the cloning o f Na^-dependent excitatory amino acid transporter subtypes,
GLAST (Storck et ah, 1992), GLT-1 (Pines et al., 1992), EAACl (Kanai, 1992), and
EAAT4 (Fairman, 1995).

Molecular probes were then produced which allowed for

identification o f the tissue distribution o f these transporter subtypes. The initial studies
examining the localization of EAATs involved mRNA studies utilizing adult mammalian
tissue preparations.

More recently, localization studies using antibodies generated

against the various transporter subtypes determined localization via immunocytochemical
and immunohistochemical methods, again in mature mammalian CNS systems. These in
vitro and in vivo studies provide insight into the multiple tasks that the transporters
execute in their regulation o f extracellular L-GLU concentrations. Additionally, these
studies set the accepted standards for cellular localization: GLAST and GLT-1 being
described as ‘glial glutam ate transporters’, EA A C l as the ‘neuronal glutamate
transporter’, and EAAT4 as being restricted to cerebellar Purkinje neurons.

However,

more recent results have revealed that these presumed transporter distribution patterns are
not absolute. Studies have continued to utilize subtype specific antibodies to further
elucidate cellular and subcellular localization o f the EAATs in a variety of in vitro and in
vivo preparations throughout each of the stages of development.
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Determining transporter localization and subtype specific roles in excitatory
transmission and excitotoxicity provides the potential for the development of agents with
which to regulate transporter-mediated processes. Numerous investigations focusing on
transm ission, transport, and L-GLU mediated excitotoxicity have utilized cerebellar
granule neuron cultures as a model experimental system. These cultures represent a
glutam atergic neuronal system and provide a highly controlled environment for
experimentation. Additionally, these cultures are useful because neurons and glia are
easily distinguished at the microscopic level and because CGNs can be cultured in the
absence of glia. The present study characterizes the cellular localization of the Na^dependent, high affinity L-GLU transporters, GLAST, GLT-1, EA A Cl, and EAAT4, in
primary cerebellar granule neurons (CGNs) and mixed CGN/glial cell cultures prepared
from 7-day-old rat cerebella. Our results demonstrate that GLAST, GLT-1, EAACl, and
EAAT4 are found in granule neurons and that GLAST and EAAT4 are also present on
astrocytes provides important data towards defining the functional importance of these
transporters.

C ellular D istribution o f E A A T s

In the present in vitro study, GLAST predominantly localizes to granule neurons
in both culture types. Additionally, GLAST localizes to some, but not all, GFAP positive
astrocytes. Our demonstration o f GLAST localization to neurons, contrasts with initial
reports dem onstrating that GLAST is restricted to mature glial cells, particularly
Bergmann glia in the cerebellar cortex (Storck et al., 1992; Schmitt et al., 1997). More
recent studies, however, demonstrate that this presumed astroglial transporter is also
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expressed in neuronal cells. These studies report that GLAST is localized to neurons in
mature cerebellar tissue slices (Rothstein et al., 1994), as well as in human CNS tissue
(Arriza et al., 1994).

Similar findings have also been reported for cultures of rat

hippocampal neurons (Mennerick, 1998). Therefore, our finding that both cerebellar
granule neurons and astrocytes express GLAST is consistent with the more recent
conclusions that GLAST may function as either a neuronal or astrocytic L-GLU
transporter.
Similarly, our results provide evidence that neurons also express the L-GLU
transporter, GLT-1. We demonstrate GLT-1 expression is localized to cerebellar granule
neurons in CGN cultures and mixed CGN/glial cell cultures. More specifically, we show
that the majority o f staining is present on neuronal processes and cell bodies. Again, our
findings contrast with initial cloning experiments that showed GLT-1 mRNA and protein
were largely restricted to astrocytes in adult rat preparations (Pines et al., 1992; Rondo et
al., 1995; Danbolt et al., 1998). However, in addition to the present study, more recent
reports have also demonstrated that GLT-1 is expressed by neurons (Mennerick, 1998).
GLT-1 expression has been described in glial cell-depleted cultures of cortical neurons
and in certain neurons o f the retina (Wang et al., 1994). Additionally, GLT-1 mRNA has
been detected in neurons from the hippocampus (Torp et al., 1994) and from several other
regions (Schmitt et al., 1997). Thus, our results provided further evidence that CNS
expression o f the L-GLU transporter GLT-1 is not restricted to astrocytes as originally
hypothesized.
Our results demonstrate that EAACl is localized to granule neurons, grown both
in the presence and absence o f astrocytes, and that EAACl is not localized to GFAP
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positive astrocytes. These findings are in agreement with initial cloning studies that
reported observing only neuronal EAACl localization (Kanai, 1992; Vandenberg, 1998),
not only in rat (Velaz-Faircloth et al., 1996), but also in humans (Arriza et al., 1994).
Our immunocytochemical data are consistent with the specific expression o f EAAC1 in
neurons, since double labeling using an antibody against GFAP verified that astrocytes, at
least in 10-day-old cultures, were not contributing to the observed transporter
immunoreacti vity.
We found EAAT4 protein localized predominantly to astrocytes in both CGN
cultures and mixed CGN/glial cell cultures. In some instances however, neuronal cell
bodies, but not neuronal processes, exhibit EAAT4 expression.

Initial studies

dem onstrated that EAAT4 localizes to cerebellum, specifically Purkinje neurons
(Fairman, 1995). However, our results suggest that EAAT4 is not strictly localized to
Purkinje neurons, but is also present on granule neurons in addition to cerebellar
astrocytes. To date, this is the first report demonstrating that EAAT4 can be expressed
by astrocytes. It must be noted, however, that commercial antibodies have only been
recently made available against this transporter, so future studies may find additional
examples which show that astrocytes in other brain regions do in fact express EAAT4.
As demonstrated by this project, as well as by many others, there has been
considerable variation among studies aimed at determining the cellular distribution of the
various EAAT subtypes. There are, however, significant variables that may account for
differences in the results from these studies. Variations in transporter expression patterns
during development have been reported, as well as differences related to in vitro culturing
conditions (Gegelashvili and Schousboe, 1997a). Developmental expression patterns of
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L-GLU transporter subtypes have been the subject o f several reports (Sutherland et al.,
1996; Bar-Peled et al., 1997; Yamada et al., 1997). L-Glutamate is thought to participate
in several processes that occur during neuronal development, such as cell migration, cell
differentiation, and neuronal and astroglial proliferation (Bar-Peled et al., 1997). In this
respect, L-GLU transporters may play a role in the developmental processes by
regulating L-GLU levels. Currently, it is known that transporter expression patterns
change throughout CNS maturation. GLAST protein and mRNA are found at low levels
in the postnatal cerebellum and increase to reach adult expression levels near postnatal
day 26 (Furuta et al., 1997). Additional studies suggested that GLAST expression may be
both neuronal and glial in early development, switching to a strict astroglial expression
pattern in the mature brain (Bar-Peled et al., 1997). Our investigation provides further
evidence demonstrating GLAST expression in the cerebellum at an early developmental
stage in both neurons and astrocytes. Like GLAST, GLT-1 levels also increase during
development. GLT-1 levels are virtually undetectable at birth, gradually increasing in the
first month o f development, reaching peak levels near postnatal day 26 (Kondo et al.,
1995; Furuta et al., 1997; Swanson et al., 1997). This may explain why we did not see
GLT-1 expression in astrocytes in our experiments. Interestingly, neuronal EAACl
expression decreases throughout development. EAACl expression is highest early in
development with peak levels observed near postnatal day 5 (Rothstein et al., 1994;
Yamada et al., 1996). We demonstrate strong expression of EAACl by granule neurons
in our cultures, consistent with previously described developmental expression patterns.
The presence o f EAAT4 mRNA in neurons has been shown to increase dramatically
during maturation, especially during the period associated with synaptogenesis in rat
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(Furuta et al., 1997). However, EAAT4 protein expression in Purkinje cells may occur
much later in development, being detectable primarily in the mature cerebellum (Yamada
et al., 1996). Our results show that cell types, other than just Purkinje neurons may
express EAAT4 especially early in development.
Several hypotheses have been developed regarding alterations in transporter
expression patterns observed during development. Potentially, cells may have an
uncom m itted L-GLU transporter phenotype, with cell-type specificity for L-GLU
transporter phenotype occurring with maturity (Yamada et al., 1996). Another possibility
is that neurons may express a greater diversity o f transporter subtypes during
development (Yamada et al., 1996). Such a possibility is consistent with the hypothesis
that L-GLU transport by neurons predominates over astroglial transport of L-GLU during
development (Furuta et al., 1997). While these hypotheses have yet to be proven, our
results demonstrating neuronal expression o f GLAST, GLT-1, EA A C l, and EAAT4
appear consistent. Additionally, our results are consistent with the idea that a different
group o f transporters may be responsible for the clearance of extracellular L-GLU early
in development than in the mature brain (Bar-Peled et al., 1997). The diversity of EAAT
subtypes observed during the developmental process suggests multi-functional roles for
L-GLU transporters. Before synapses have completely formed, L-GLU transporters may
play additional roles beyond m aintaining low concentrations o f L-GLU in the
extracellular space.
Several reports have demonstrated that in vitro culture systems exhibit patterns of
L-GLU transporter expression which differ from those observed in vivo, suggesting that
culture conditions may influence L-GLU transporter activity and expression [Kondo,
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1995 #27; Swanson, 1997 #56]. Interestingly, our results did not show a recognizable
change in neuronal transporter expression when the cells were grown in the presence or
absence o f astrocytes. Others have shown changes in expression, particularly with GLT1, although, these studies were not performed in cerebellar granule neuron cultures.
Specifically, studies have demonstrated that GLT-1 expression is severely downregulated
in cultured cortical astrocytes when compared to in vivo findings (Gegelashvili et al.,
1996; Gegelashvili and Schousboe, 1998).

Further evidence suggesting changes in

transporter subtype expression due to growth conditions is provided by studies that show
transporter sensitivity to uptake inhibitors differ when compared between in vitro and in
vivo experiments (Gegelashvili and Schousboe, 1998). Molecular expression and activity
of L-GLU transporters are also amenable to differential regulation by a number of
bioactive substances (Gegelashvili et al., 1996). For example, a deficiency o f certain
m etabolites in the culturing m edia may be involved in regulation o f transporter
expression (Gegelashvili et al., 1996). Interestingly, it has been reported that certain
neuronal growth factors (e.g., nerve growth factor, fibroblast growth factor, brain-derived
neurotrophic factor) may be essential for the expression of GLT-1 in astrocytes (Drejer
et al., 1983b; Gegelashvili et al., 1997; Swanson et al., 1997; Figiel and Engele, 2000).
Therefore, L-GLU transporter expression patterns observed in this investigation, may be
a reflection of the ex vivo environment o f the cultured cells. Specifically, the expression
of GLAST by cerebellar granule neurons, the lack of astrocytic GLT-1 expression, and
expression o f EAAT4 by both cerebellar granule neurons and astrocytes, may be
attributable to the conditions in which these cells were grown.
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F u n ction al Significance

As stated before, it is currently thought that L-GLU transporters may play a role
in transmitter recycling, signal termination, and excitotoxic protection. In this respect,
determining the cellular and subcellular distribution o f the transporters should provide
valuable insight into subtype specific roles in these processes. For example, it can be
presumed that transporters must be localized to the synaptic cleft region to participate in
signal termination. In contrast, localization to areas outside o f the synaptic cleft may be
indicative o f roles other than signal termination. Indeed, cell body or axonal localization
may indicate that the transporters are playing a metabolic role in these cells, such as
protein synthesis or precursor acquisition for neuro transmitter synthesis. Based on
studies performed to date, neuronal expression o f EAATs is postulated to function in
excitotoxic protection and in metabolism. Unfortunately, in this investigation the image
resolution could not provide information as to the subcellular localization of the
transporters.

Therefore, we could not determine whether the various transporters

demonstrated distinct subcellular patterns o f expression, showing either cell body
localization or synaptic cleft localization.
GLAST localization to the synaptic cleft would be consistent with the presumed
role in clearance o f neurotransm itter for signal term ination, however, GLAST
localization to areas outside o f the synaptic cleft would suggest that GLAST plays a more
significant role in precursor uptake. Kinetic studies have shown that GLAST has a
higher Km (77 fxM) for L-GLU than both GLT-1 (2 |im ) and EA A Cl (17 jim)
(Gegelashvili and Schousboe, 1997b). This information supports the idea that GLAST
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functions as a lower affinity reserve uptake system backing up the higher affinity systems
in CNS tissue (Kanai et al., 1994a).

L-Glutamate uptake through GLAST has been

suggested to play a role in metabolism due the localization of GLAST to peripheral tissue
as well as CNS tissue. Therefore, in addition to terminating the action of synaptically
released L-GLU at central synapses, the localization of GLAST to glutamatergic neurons
may suggest additional functions in the regulation of other aspects of L-GLU signaling.
It is generally well accepted that L-GLU transporters play a physiological role in
astrocytes. While the predominant astrocytic L-GLU transporter GLT-1 plays a major
role in the glutamate-glutamine shuttle, our findings demonstrating astrocytic GLAST
localization suggests that this EAAT may also play a role in the glutamate-glutamine
shuttle. Astrocytic GLAST may allow for L-GLU uptake leading to the subsequent
metabolic conversion to glutamine by the action o f glutamine synthetase, an enzyme that
is highly concentrated in astrocytes. Neighboring neurons are then able to use the
released glutamine as a precursor for L-GLU synthesis. Thus, astrocytic expression of
GLAST may provide additional glutamate-transporting capacity (Kanai et al., 1994b) that
may serve to protect neurons from excitotoxicity.
Gegelashvili et al., 1997 reported that the ‘glial L-GLU transporter’ GLT-1, has
the highest affinity for L-GLU when compared to other EAATs (Gegelashvili and
Schousboe, 1997b). It is also known that glial cells are responsible for clearing the
majority o f synaptically released L-GLU. Although, L-GLU uptake sites have also been
shown to exist on neurons (Gegelashvili and Schousboe, 1998). Interestingly, Mennerick
et al. (1998) showed that neuronal GLT-1 participates in the clearance o f synaptically
released L-GLU (Mennerick, 1998). Therefore, cerebellar granule neuron expression of
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GLT-1 may represent an alternate mechanism for clearance o f synaptically released LGLU in the cerebellum.

A subcellular distribution pattern for GLT-1 is necessary to

establish whether GLT-1 plays a role in excitotoxic protection or signal termination in
granule neuron cultures.

Our demonstration of GLT-1 localization to neuronal cell

bodies in CGN cultures may be indicative of an alternate role in neurotransmission.
N euronal expression o f EAACl has previously been documented (Fairman,
1995).

To date, glial expression o f EAACl has only been shown in tumor cells,

specifically rat C6 glioma cell lines and several human tumors o f glial origin (Kanai,
1992; Kanai et al., 1994a; Rothstein et al., 1994; Vandenberg, 1998), and not in primary
cultures or tissue sections. Neuronal expression of this high affinity L-GLU transporter
(Km 17|im) suggests that neuronal uptake of L-GLU plays an important role in excitatory
amino acid neurotransmission. We demonstrate EAACl localization predominantly to
neuronal cell bodies and not neuronal filaments or astrocytes. This finding suggests that
EA A Cl probably does not play a major role in signal termination, but may rather
function in a capacity more closely linked to metabolism and excitotoxic protection in
these culture systems. However, not all o f the information known regarding EAACl is
consistent with this role for EAACl in granule neurons. EAACl mRNA is found in
GABAergic neurons isolated from rat preparations (Rothstein et al., 1994; Gegelashvili
and Schousboe, 1998). These data raise the possibility that EA A Cl plays a role
transporting the necessary precursors for G ABA synthesis, instead of or in addition to, a
role in L-GLU clearance. Localization of EAACl to peripheral tissue as well as CNS
tissue is consistent with this idea.
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EAAT4 expression on cerebellar granule neurons as well as astrocytes within our
culture system provides little insight as to the physiological role o f EAAT4. EAAT4
localization on granule neuron cell bodies suggests this transporter does not play a
prom inent role in signal term ination.

However, our dem onstration o f EAAT4

localization on glial cells lying in close proximity to clustered neurons suggests astrocytic
EAAT4 may play a role in signal termination, excitotoxic protection, and/or the
glutamate-glutamine cycle. A more complete subcellular distribution of this transporter
in both neurons and glia is necessary to elucidate the functional significance of this
transporter and develop specific therapies for the treatment of various disease states.

L -G lutam ate T ransporters as Therapeutic Targets

Selective pharmacological agents are required to further elucidate the specific
roles o f L-GLU transporters in the pathogenesis o f neurological disorders. Because LGLU transporters are widely distributed throughout the CNS, they may prove to be
valuable as potential molecular targets for both neuropsychiatrie and neurodegenerative
disorders (Lipton and Rosenberg, 1994; Dunlop et al., 1999). Determining subtype
specific pharmacology through the use o f transport inhibitors may lead to a better
understanding of the respective roles that transporters play in normal and pathological
states (Rothstein et al., 1996; Bergles and Jahr, 1997). Targeting these transporters for
the development o f drugs was initially considered to be counterintuitive because total
inhibition of L-GLU transport was assumed to have neurotoxic effects.

However, it is

now becoming apparent that not all L-GLU transporters contribute equally to signal
termination, transmitter recycling, and excitotoxicity. Therefore, partial inhibition o f a
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subset o f L-GLU transporters may be therapeutically useful in the treatment of
neurological disorders.

For example, partial inhibition o f L-GLU transport may

beneficial in schizophrenia, a condition in which reduced glutamatergic output is thought
to contribute to pathogenesis (Robinson, 1998). In the case o f epilepsy, excessive LGLU is released and a strategy to enhance the activity o f L-GLU transporters would be
desirable (Olney et al., 1986; Akbar et al., 1998).
Developing L-GLU transport inhibitors may also be effective in the treatment of
pathogenic conditions where reverse transport is implicated. Reverse transport occurs
when L-GLU is released by the cell through the reversal of L-GLU uptake and the
movement o f L-GLU down its concentration gradient into the extracellular space leading
to excitotoxicity (Billups et al., 1998). Reverse transport may occur in cases of ischemia
where lack of oxygen and depleted energy supply cause transmembrane ion gradients to
run down (Billups et al., 1998). Therefore, compounds that selectively block reverse
transport may be useful in limiting reverse L-GLU transport associated with ischemia.
Cerebellar granule neuron cultures are widely utilized in studies o f transporter
function that rely on pharmacological inhibitors (Campbell and Shank, 1978; Balcar et
al., 1987; Griffins et al., 1989; Lysko et al., 1994). Dihydrokainate (DHK) has been
previously identified as a selective inhibitor of GLT-1 (Monaghan et al., 1989; Bridges et
al., 1999; Koch et al., 1999; Brauner-Osborne et al., 2000).

Results obtained from our

investigation suggest that GLT-1 localizes to neurons in CGN cultures and mixed
CGN/glial cell cultures unlike some other experimental systems where GLT-1 is found
on astrocytes and not neurons. When observing transport inhibition by DHK in other
culture systems, it may have been assumed that DHK was blocking uptake in to glia not
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neurons. Therefore, results obtained in our investigation may change the interpretation of
previous transport inhibitor studies performed in CGN culture system. Additionally, our
results demonstrating cell type transporter expression in CGN cultures will be essential to
properly interpret future results obtained from pharmacological transport inhibitor studies
using this in vitro preparation.

F uture Studies

Because CGN cultures are a widely utilized system for studying glutamatergic
neurotransm ission, it is essential to precisely define specific cell-type transporter
expression patterns to proceed with future studies utilizing this system. CGN culture
systems may provide valuable insight into the regulation o f transporter expression (e.g.,
grow th factor regulation and developm ental regulation) and the design of
pharmacological agents with which to regulate transporter function (e.g., pharmaceutical
inhibitors and methods to increase transporter function such as gene therapy. Thus, our
description of transporter expression patterns in this culture system is essential to gain
further understanding into the specific roles that L-GLU transporters play in normal
physiology and pathology.
An essential step in determining functional roles of the transporter subtypes is to
fu rth er

defin e

th e

subcellular distribution patterns o f these transporters.

Im m unocytochem ical m ethods represent one potential method for determining
subcellular distribution.

Investigations could utilize antibodies against synaptic proteins

(proteins that specifically localize to the synaptic areas o f neurons) to see if they colocalize with L-GLU transporter subtypes. It is important to know which transporters
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have synaptic localization as this knowledge may allow for speculations regarding the
specific roles that transporters play in glutamatergic neurotransmission.
Future studies are also needed to develop therapies targeted toward specific LGLU transporter subtypes.

Researchers have previously explored L-GLU receptor

antagonists, metabolic inhibitors, and release inhibitors to decrease the toxic effects to
neurons by L-GLU with varying degrees o f success. The task has proven to be very
difficult due to differences in function and distribution that each transporter exhibits
depending on the nature of the uptake systems (brain slice, cell cultures, synaptosomes,
and other membrane preparations). Because L-GLU transporters represent a potential
regulatory mechanism to control the balance between physiological signaling and
excitotoxic pathology, modulation o f L-GLU transporter expression may prove to be a
strong target for novel drug discovery (Takahashi et al., 1997; During and Asthenden,
1998; Dunlop et al., 1999).
Future studies using molecular methods to transfect the various EAATs into
neurons or glia in a cell culture environment, as well as animal models of disease, may
have therapeutic value in diseases like Amyotrophic Lateral Sclerosis (ALS) and epilepsy
(Hurko and Walsh, 2000).

Evidence indicates that chronic suppression o f L-GLU

transport in ALS may be a significant factor in the pathophysiology o f this disease
(Rothstein et al., 1992).

Lin et. al showed that the presence o f aberrantly spliced

transcripts from the GLT-1 gene are responsible for the reduction o f functional GLT-1
protein and activity observed in ALS brains (Lin, 1998). Therefore, gene therapy aimed
at enhancing expression o f the GLT-1 transporter in ALS patients is a therapeutic goal.
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In order to utilize CGN cultures to design future gene therapy experiments, it is
essential to understand which transporter subtypes should be expressed and which cell
type to attempt to increase expression.

For example, if the goal were to increase

expression of GLT-1 into neurons, it would be valuable to determine whether or not
neurons can express GLT-1 at some time in their developmental process. Data obtained
from our investigation shows that cerebellar granule neurons do have the capacity to
express GLT-1. Thus, transfecting neurons with GLT-1 may be a reasonable strategy for
gene therapy.
With cell-type specific expression patterns o f the L-GLU transporters in CGN
cultures now known, results obtained from future studies utilizing these cultures may be
more precisely interpreted. Utilizing this in vitro culture system may prove to be a
valuable tool gaining a more precise understanding of transporter function. Additionally,
this in vitro culture system may be a useful tool for development o f specific therapies
targeted towards the L-GLU transporters.
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